EverSource Wealth Advisors LLC Raises Position in Eli Lilly and Company $LLY

EverSource Wealth Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 34.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,620 shares of the company’s stock after purchasing an additional 2,491 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $8,848,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Spire Wealth Management raised its holdings in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after acquiring an additional 592 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares during the last quarter. Iams Wealth Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $754,000. May Hill Capital LLC increased its position in Eli Lilly and Company by 131.6% during the 4th quarter. May Hill Capital LLC now owns 3,170 shares of the company’s stock worth $3,408,000 after purchasing an additional 1,801 shares in the last quarter. Finally, Caisse Des Depots ET Consignations raised its stake in Eli Lilly and Company by 17.3% in the 4th quarter. Caisse Des Depots ET Consignations now owns 10,834 shares of the company’s stock valued at $11,643,000 after purchasing an additional 1,600 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and investors remain optimistic about Lilly’s earnings momentum. The company generated $19.8 billion in first-quarter revenue, up roughly 55.5% year over year, and recent analyst price targets have generally exceeded the current trading level. The median target from 14 analysts is $1,336, with targets as high as $1,500. Eli Lilly Stock Opinions on Growth and AI Ventures
• Positive Sentiment: Lilly’s expanding oncology and newer-medicine portfolio is expected to contribute meaningfully to second-quarter results, supplementing demand for its GLP-1 franchise. This diversification could reduce reliance on weight-loss and diabetes products while supporting long-term revenue growth. Here’s How LLY’s Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
• Positive Sentiment: The company is making a reported $2.8 billion investment aimed at expanding growth beyond GLP-1 drugs. Investors also highlighted Lilly’s investments in artificial-intelligence drug discovery, data infrastructure and potential opportunities in emerging treatment categories. Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
• Neutral Sentiment: Institutional trading was mixed: 2,169 investors added shares in the latest quarter, while 1,653 reduced positions. Several large holders made sizable sales, offset by substantial purchases from other institutions. Social-media commentary also emphasized Lilly’s revenue scale and sustained earnings power, but these discussions are not formal company guidance. Eli Lilly Stock Opinions on Growth and AI Ventures
• Negative Sentiment: Insider activity included one reported open-market sale by an executive involving 2,500 shares. While the transaction is relatively small compared with Lilly’s market value, it provides a modest counterpoint to the otherwise bullish coverage. Eli Lilly Stock Opinions on Growth and AI Ventures

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Sanford C. Bernstein upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Finally, Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Trading Up 2.1%

Shares of LLY stock opened at $1,222.61 on Wednesday. The firm’s 50-day simple moving average is $1,144.84 and its 200-day simple moving average is $1,041.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45. The firm has a market cap of $1.15 trillion, a P/E ratio of 43.43, a PEG ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.03 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.